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Abstract The nematode Spirocerca lupi is a major canine
parasite in warm regions of the world, classically causing
parasitic nodules in the esophagus, aortic aneurysms, and
spondylitis. This study evaluated the preventive efficacy of
monthly treatment with imidacloprid 10%/moxidectin 2.5%
spot-on (Advocate® for dogs) administered over a period of
9 months in young dogs naturally exposed to S. lupi on
Réunion island. One hundred and twelve puppies, aged
from 2.0 to 4.0 months and with a negative spirocerca fecal
examination at inclusion, completed the study. They were
randomly allocated to two groups. Group A puppies (n=58)
received nine spot-on treatments with Advocate® at the
minimum dose of 2.5 mg moxidectin/kg bw at monthly
intervals. Control group B puppies (n=54) received no
treatment for S. lupi. During the study, regular clinical and
fecal examinations were performed, as was final upper
gastrointestinal endoscopy. Endoscopy showed that 19 dogs
from group B had spirocerca nodules, corresponding to a
prevalence of 35.2% in dogs aged 12 to 14 months. In
contrast, only one dog from group A had a nodule,
corresponding to a preventive efficacy of 94.7% (p<
0.0001). None of the 378 fecal examinations were positive
for spirocerca. This study confirms a high prevalence of
canine spirocercosis on Réunion and shows that infestation
occurs in very young puppies. Furthermore, it demonstrates
that monthly spot-on administration of a combination of
imidacloprid 10%/moxidectin 2.5% (Advocate® for dogs)
in puppies starting at the age of 2 to 4 months achieves
effective and safe prevention of canine spirocercosis.
Introduction
Spirocerca lupi (Nematoda: Spirurida, Thelaziidae) is a
parasite of dogs that can also affect other animals, mainly
carnivores such as foxes, wolves, coyotes, and wild Felidae.
The life cycle is indirect, with coprophagous beetles acting
as intermediate hosts. A large variety of Amphibia, reptiles,
birds, and small mammals such as hedgehogs, mice, and
rabbits can act as paratenic hosts (Bourdoiseau 2000).
The adult S. lupi occurs in a nodular mass in the wall of
the esophagus. The female lays embryonated eggs that
leave the nodule via an opercule and are shed in the host's
feces. Eggs are ingested by the intermediate host, coproph-
agous beetles, and develop to the infective (L3) stage
within 2 months. In the carnivore host, the infective larvae
penetrate the gastric mucosa, and migrate within the walls
of the gastric arteries to the thoracic aorta. About 3-months
post-infection, the larvae leave the aorta and migrate to the
esophagus where they provoke the development of granu-
lomas as they mature to adults over the next 2 to 3 months
(Fig. 1). The prepatent period is usually 4 to 5 months
(Soulsby 1986; Bourdeau 1985; Bourdoiseau 2000).
The clinical signs associated with canine spirocercosis
depend on the location of the lesions. The development of
chronic esophagitis leads to vomiting and regurgitation,
weakness, emaciation, loss of weight, anemia, or bleeding
(Mazaki-Tovi et al. 2002). Other signs include sudden death
due to the rupture of an aortic aneurysm (Rinas et al. 2009)
or the rupture of the esophagus, and evolution of the nodules
into tumors (Bourdoiseau 2000;R e c h e - E m o n o te ta l .2001).
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migration of the larvae and adults in the tissues. The most
frequent lesions are esophageal nodular masses and granu-
lomas, aortic scars, and aneurysms (Fox et al. 1988).
Spondylitis and spondylosis of the caudal thoracic vertebrae
may be observed, as may the neoplastic transformation of
granulomas into fibrosarcoma or osteosarcoma (Soulsby
1986;J o h n s o n1992; Ranen et al. 2004; Van der Merwe et
al.2008). Aberrant migration of S. lupi worms can occur, and
the resulting nodules can affect various organs including the
thoracic organs, the gastrointestinal tract, the urinary system,
and the subcutaneous tissues (Mazaki-Tovi et al. 2002).
The diagnosis of spirocercosis usually consists in the
detection of the characteristic eggs by fecal flotation
(Markovics and Medinski 1996; Bourdoiseau 2000),
although sensitivity is low due to intermittent egg shedding.
Endoscopy is a reliable examination to detect the esophageal
and gastric S. lupi nodules (Reche-Emonot et al. 2001).
Additional examination includes radiographs to detect the
nodules or resulting tumors in affected organs (i.e., esophagus,
thoracic vertebrae etc.; Mazaki-Tovi et al. 2002).
S. lupi is a cosmopolitan parasite which affects canines
mainly in tropical and subtropical areas. Clinical cases or
observations in domestic dogs have been reported in a large
number of countries including South Africa (Van der Merwe
et al. 2008), Israel (Ranen et al. 2004, 2008;D v i re ta l .
2008), Argentina (Rinas et al. 2009), Brazil (Tudury et al.
1995), Kenya (Murray 1968), Iran (Naem 2004), India
(Chandrasekar et al. 1995) and the southern US (Dixon and
McCue 1967). Spirocercosis is observed very occasionally in
France (Bourdeau 1985), but it is a major canine disease on
Réunion (Indian Ocean). An epidemiological and clinical
study performed on Réunion showed a clinical prevalence of
4.8% (120 confirmed clinical cases out of 2,498 examined
dogs), and an asymptomatic prevalence of 27.5% (14
positive coproscopic examinations out of 51 examined
asymptomatic dogs; Reche-Emonot et al. 2001).
Of the anthelmintic drugs which have been tested to
treat spirocercosis, macrocyclic lactones are the most
interesting. In the majority of study protocols, the drug
was administered subcutaneously. Ivermectin has been
reported to be ineffective against S. lupi (Last and Smith
2007). However, ivermectin (1,000 μg/kg body weight
(bw)) in combination with nitroxynil (10 mg/kg bw)
administered subcutaneously was reported to be successful
in treating infected dogs on Réunion in 81.6% of cases. A
clinical cure was achieved in animals following both
endoscopic evaluation and fecal flotation (Reche-Emonot
et al. 2001). Mylonakis et al. (2004) reported that two
doses of ivermectin (600 mcg/kg bw, s.c., 2-weeks apart)
in combination with oral prednisolone (0.5 mg/kg bw
twice a day for 2 weeks followed by dose tapering)
promoted nodular regression and suppressed fecal egg
shedding for up to 2 months following the last treatment.
Doramectin has produced positive results in both
spontaneous and experimental cases. Berry (2000)d e m -
onstrated that 200 μg/kg bw of doramectin injected s.c. at
14-day intervals for three subsequent treatments was
effective in treating spirocercosis in 5/7 infected animals.
Doramectin was again shown to be effective by Lavy et al.
(2002) using an alternative dosing regimen of 400 μg/kg
bw injected s.c. every 14 days for six treatments, followed
by monthly dosing until resolution of the parasitic nodule.
Reduction of eggs shedding was observed in the feces as
little as 3–10 days after the first treatment.
Kelly et al. (2008) reported that milbemycin oxime
(11.5 mg p.o. on days 0, 7 and 28, and then monthly)
stopped the shedding of S. lupi eggs after 3–44 days in six
treated dogs and promoted nodular regression.
Thereare few reports on theprevention of spirocercosis. The
prophylactic effect of doramectin was investigated by Lavy et
al. (2003) in experimentally infested dogs. Five dogs were
injected subcutaneously with doramectin (400 μg/kg bw on
three occasions 30–days apart) and then inoculated with 40
infectious S. lupi larvae (L3) 1 month after the last doramectin
treatment. Although doramectin did not entirely prevent
canine spirocercosis, it reduced the clinical signs associated
with infection and delayed and reduced egg shedding.
Despite the positive results obtained with the reported
treatment regimens with doramectin and ivermectin against
S. lupi, the drugs are used off-label and have to be injected,
which is inconvenient, time-consuming, and expensive for
owners. It was therefore interesting to investigate the efficacy
of a macrocyclic lactone (moxidectin) available in a more
user-friendly spot-on formulation which is approved for use in
dogs for a number of other internal parasitic infections.
The purpose of the study was to evaluate the preventive
effects of monthly treatment with imidacloprid 10%/
moxidectin 2.5% spot-on (Advocate®) administered over
a period of 9 months in comparison to an untreated control
Fig. 1 Adult Spiroceca lupi
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young dogs naturally exposed to S. lupi on Réunion island.
Materials and methods
Study design
The study was designed as a multicentre, randomized,
controlled, blinded (endoscopy and fecal examinations
were blinded) clinical field study conducted in three
veterinary practices located on Réunion island (Indian
Ocean) in accordance with Good Clinical Practice (VICH
GL9 (GCP), Step 7) as adopted by the CVMP in June 2000.
The effect of treatment was compared to a negative control
group (untreated).
The study protocol was based on ten visits at 4-week
intervals for the treated group, and four visits for the dogs in the
untreated group (V1=inclusion, V2=8th month, V3=9th
month, V4=10th month/termination). The main efficacy
criterion was the non-occurrence of infection as confirmed by
fecal and endoscopic examination at month 10 (end of the
study).
Study animals
In view of the purpose of the study (evaluation of the
preventive efficacy of the combination imidacloprid 10%/
moxidectin2.5% spot-on), the prepatent period of the parasite
(4 to 5 months) and the significant prevalence of the parasite
onRéunion,onlyveryyoungdogs(from2to4monthsofage)
were included in order to make sure that they were free of
spirocerca infection at the time of inclusion.
One hundred and twelve (112) puppies naturally exposed
to spirocerca infection completed the study during the
period from July 2007 to March 2009. The study animals
consisted of 56 males and 56 females of various breeds. At
the time of inclusion, the age of the puppies ranged from
2.0 to 4.0 months (median, 3 months).
The puppies were randomly allocated to two groups.
Group A puppies (n=58) received nine spot-on treatments
with Advocate® (imidacloprid 10%/moxidectin 2.5% spot-
on) at monthly intervals. They consisted of 27 males and 31
females, aged from 2.0 to 4.0 months (mean, 2.8 months).
Group B puppies (n=54) received no treatment for S. lupi
and consisted of 29 males and 25 females, aged from 2.0 to
4.0 months (mean, 2.9 months).
The main data describing the puppy population are
shown in Table 1.
Treatment
In group A, animals were treated with imidacloprid 10%/
moxidectin 2.5% spot-on (Advocate® for dogs; Bayer
Animal Health GmbH, Leverkusen, Germany) at the
minimum recommended dose of 2.5 mg moxidectin/kg
bw s.c. (equivalent to 1 mL Advocate®/10 kg bw). Given
that Advocate® for dogs is marketed in pre-dosed pipettes,
the administered dose of moxidectin ranged from 2.5 to
6.25 mg/kg bw as indicated in Table 2.
Clinical examinations
Clinical examinations were performed at each visit (i.e. ten
times for group A and four times for group B). The following
clinicalparameterswereevaluated:generalbehavior,appetite,
Group A (treated) Group B (untreated)
Total population n=58 n=54
Sex Male n=27 n=29
Female n=31 n=25
Age (in months) Minimum 2.0 2.0
Maximum 4.0 4.0
Mean 2.8 2.9
Length of coat Short n=32 n=34
Average n=20 n=13
Long n=6 n=7
Altitude of the household (m) Minimum 0.0 0.0
Maximum 1,400 1,400
Mean 389.9 386.9
Total number of dogs in the household Minimum 1.0 1.0
Maximum 6.0 10.0
Mean 1.8 2.0
Table 1 Description of the
study animals
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musculo-skeletal system, skin, and other clinical signs.
Fecal examinations
Fecal examinations were carried out for both A and B groups
on four occasions: at V1 (inclusion visit) and at the last three
visits(correspondingtoV8,V9,andV10forgroupAandV2,
V3, and V4 for group B). Fecal samples were examined using
a magnesium sulfate (MgSO4, density 1.28) flotation method
and the number of S. lupi eggs per gram of feces was
recorded for each sample (Thienpont et al. 1979).
The fecal examinations were blinded, so the laboratory
did not know which group the evaluated samples originated
from.
Endoscopy
Upper gastrointestinal (esophagus and stomach) endoscopy
was performed on each dog during the last visit,
corresponding with the 10th month of the study follow-up,
byaclinicianotherthantheonewhoexaminedthedogduring
the study (blinded endoscopy). Endoscopies were performed
using mainly Optomed® flexible four-way directional tip
(7.9 mm) endoscopes. For endoscopy, the dogs were
anesthetized intravenously with ketamine (Clorketam®
1000, Vetoquinol, 5 mg/kg bw i.v.) and xylazine (Rompun®,
Bayer, 1 mg/kg i.v.) in some cases followed by a volatile
anesthetic such as isoflurane. The location (esophagus or
stomach), size, number, and type of nodules (simple,
operculated, or ulcerated nodule, tumor) were recorded as
described by Reche-Emonot (Reche-Emonot et al. 2001).
Calculation of preventive efficacy
The effect of nine monthly treatments on the prevention of
canine spirocercosis was calculated according to the
following formula:
%Efficacy ¼ð Number positive dogsðcontrolgroupÞ
 Number positive dogsðtreatment groupÞÞ
 100=Number positive dogsðcontrol groupÞ
Statistical analysis
The analysis was performed with the validated program
Testimate Version 6.4 from IDV Gauting (validation of
software, hardware, and user according to FDA 21 CFR Part
11) and Report Version 6.6 from IDV Gauting. All evaluation
steps were documented in full and in-process controls were
performed and also documented (time stamps, audit trail).
The primary criteria “non-occurrence of infection as
confirmed by parasitological or clinical (endoscopic)
examination at month 10 (end of study)” was assessed
using the 2×2 table test (Fisher's exact test) for treatment
group A vs. group B (untreated control group).
The hypothesis for the superiority test was: H0: pR−pT≤
0.05 and H1: pR−pT>0.05 (pR: prevalence in reference group,
pT: prevalence in treatment group A). The multiple-level alpha
for the experiment was defined as a one-sided alpha=0.10.
The medical relevance of the differences between the
groups was quantified using the Mann–Whitney superiority
measure (MW) with its one-sided 90.0% confidence
interval as the corresponding effect size. The efficacy
analysis was performed using the PP population (per
protocol).
All secondary criteria (efficacy and safety) were ana-
lyzed descriptively, using non-parametric tests as well if
appropriate. Descriptive statistics were performed for all
criteria: for continuous data: valid n; absolute values,
change from baseline, percentage change from baseline;
average, mean, and standard deviation, minimum, lower
quartile, median, upper quartile, maximum per group; for
category data: absolute and percentage values per group.
Results
Fecal examination
During the study, 196 fecal samples were collected and
analyzed according to the protocol in group A (treated), and
182 in group B (untreated). In comparison with the
expected collection of samples (i.e., four fecal samples per
dog during the study), 36 fecal samples were missing in
group A, and 34 in group B.
Table 2 Applied dose of Advocate® for dogs
Weight of the dog [kg] Size of the pipette Volume of the pipette [ml] Imidacloprid [mg/kg bw] Moxidectin [mg/kg bw]
≤4 kg Advocate for small dogs 0.4 minimum 10 minimum 2.5
4–≤10 kg Advocate for medium dogs 1.0 10–25 2.5–6.25
10–≤25 kg Advocate for large dogs 2.5 10–25 2.5–6.25
25–≤40 kg Advocate for very large dogs 4.0 10–16 2.5–4
>40 kg Appropriate combination of pipettes
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analyzed.
Endoscopy
Endoscopy was performed 10 months after inclusion in the
112 dogs and showed that 20 dogs were infested with
S. lupi. The presence of nodules was observed in 19 dogs
out of 54 (35.2%) in group B (untreated) and in only one
dog out of 58 (1.7%) in group A (treated). The presence of
spirocerca nodules in the treated group is statistically
significantly lower (p<0.0001) than in the untreated group.
This demonstrates the high preventive efficacy of the
combination of imidacloprid 10%/moxidectin 2.5% spot-
on against natural spirocerca infestation.
The location of the observed nodules was mainly
esophageal (19 cases out of 20). Only one dog in group B
had one stomach nodule, but no esophageal nodule.
Out ofthe 20 infested cases, simple nodules wereobserved
in 11 dogs, operculated nodules in 13 dogs (Fig. 2), and
ulcerated nodules in only two dogs. No tumoral form was
observed. The size of the esophageal simple nodules ranged
from 0.5 to 1.5 cm (average 0.9 cm). The range was 1.0 to
2.0 cm (average 1.4 cm) for operculated nodules, and 0.5 to
2.0 cm (average 1.25 cm) for ulcerated nodules.
Endoscopy showed that infested dogs had mainly one
nodule. Only four dogs from group B had two nodules, and
two dogs had three nodules. The main findings of the
endoscopic examination are presented in Table 3.
Calculation of efficacy
Based on the absence of nodules in the esophagus, monthly
treatments with imidacloprid 10%/moxidectin 2.5% spot-on
(Advocate®) administeredovera periodof9monthstoyoung
dogs aged 2–4 months achieved a protection rate of 98.3%
(p<0.0001) against spirocerca infection. None of the treated
dogs (group A) had parasitic nodules in the stomach. Since
the situation was very similar in the group B dogs
(untreated), where only one dog out of 54 had a stomach
nodule, no statistical difference between the groups could be
established for this parameter. Comparison with the group B
dogs (untreated) with esophageal or stomach nodules (n=19
out of 54) shows a preventive efficacy rate of 94.7% and
establishes the statistical superiority of group A over group B
(Fisher's exact test, p<0.0001).
Clinical findings
Only two dogs from group B with a positive endoscopy
showed some of the classical spirocercosis signs: during the
last visit (V4) one dog showed vomiting and reduced
appetite and another dog exhibited vomiting. Among the
endoscopy-negative dogs, only one showed vomiting on
the day of the last visit (V10), all other clinical parameters
being normal. During the study, none of the group A
(treated) dogs showed any adverse event linked to
administration of the treatment, thus confirming the good
tolerance of the product.
Fig. 2 Spirocerca nodules
observed by endoscopy in dog
COZ43 from the untreated
control group. a: No nodule was
observed in the stomach part. b:
Four esophageal nodules could
be observed: three simple
nodules (sn1, sn2, sn3) and one
operculated nodule (on). c: View
showing two simple nodules
(sn1, sn2). d: View showing the
three simple nodules (sn1, sn2,
sn3) and the opercule (op) of the
operculated nodule (on)
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The purpose of the study was to evaluate the preventive
efficacy of monthly treatment with imidacloprid 10%/
moxidectin 2.5% spot-on (Advocate®) administered over
a period of 9 months in young dogs naturally exposed to
S. lupi on Réunion Island. The parameters evaluated
during the study were the presence of eggs of S. lupi in
the feces and the endoscopic detection of gastroesopha-
geal nodules, as well as the possible occurrence of typical
clinical signs.
Many studies have shown that macrocyclic lactones
(ivermectin, doramectin) used subcutaneously are effective
in the curative treatment of S. lupi. (Mylonakis et al. 2004;
Lavy et al. 2002; Reche-Emonot et al. 2001). The
preventive efficacy of doramectin administered subcutane-
ously was evaluated in one experimental study (Lavy et al.
2003), but this showed that efficacy was not complete (2/5
treated dogs still showed radiographic changes). In the
current study, the preventive efficacy of moxidectin was
tested as a spot-on formulation (Advocate®), which makes
regular administration easier for the pet owner. At the end
of the study, 57/58 dogs from group A (98.3%) were
spirocerca-free against only 35/54 dogs from group B
(64.8%): this result confirms the high degree of preventive
efficacy (94.7%, p<0.0001) of the tested formulation.
Spot-on application requires the treated animal to not be
bathed during the 24 h after treatment in order to make sure
that the active ingredient (moxidectin) can penetrate through
the skin. During the study, one dog from group A lived
close to a river and had very regular baths, meaning that the
24-h bath-free period post treatment was not observed due
to lack of owner compliance. As a consequence, this was
the only “treated” dog to developed S. lupi infection.
Endoscopy showed that 19/54 dogs from the untreated
group (Group B) had spirocerca nodules, which corre-
sponds to a prevalence of 35.2% in puppies aged 12 to
14 months. This high level of infestation in young dogs
correlates with the results of the epidemiological study
performed on Réunion by Reche-Emonot (Reche-Emonot
et al. 2001), where two different analyses were performed.
First, on the basis of coproscopy and/or endoscopy, 120
dogs aged less than 6 months to 13 years (out of 2,498
clinical examinations) were found to be infested,
corresponding to a global clinical prevalence of 4.8%.
However, the infestation clearly peaked in young animals
(from 1 to 3.5 years), with 59 infested young dogs out of
120. Furthermore, in a parallel evaluation, 14 out of 51
fecal examinations of healthy dogs were spirocerca-
positive, corresponding to a prevalence of 27.5%. The fact
that, in our study, more than one third of the puppies from
group B were infested before the age of 14 months justifies
preventive measures being taken from a very young age.
Typical clinical signs of spirocercosis usually appear when
the evolution of the nodules has led to chronic esophagitis.
During this study, the experimental dogs were still young at
the endofthe follow-up(at most14monthsold).The factthat
typical clinical signs such as vomiting or loss of appetite were
observed in only two of the 19 infected dogs from the
untreated group was therefore not unexpected.
None of the 378 coproscopic examinations were positive
for spirocerca eggs, even those from infested dogs confirmed
by endoscopy. Thirteen dogs out of 20 had one or more
operculated nodules, from which the females could have shed
eggs. These negative fecal findings could be related to the
irregularsheddingofeggsbythe parasite,ortoapossiblelack
of sensitivity of flotation with MgSO4, since spirocerca eggs
are small (11–15 μm×30–40 μm) and the quantity of eggs
shed can be limited at this relatively early stage of infection.
Conclusion
Monthly spot-on administration of a combination of
imidacloprid 10%/moxidectin 2.5% (Advocate®) to
puppies at the age of 2 to 4 months for a period of 9 months
was shown to be effective and well tolerated for the
prevention of canine spirocercosis. Considering the high
prevalence of the infestation (35.2%) observed at the end of
the follow-up in untreated study animals, regular preventive
treatment of puppies living on Réunion may be recom-
mended to avoid more severe clinical disease and potential
fatalities when the infection progresses with increasing age
of the dogs.
Group A (treated; n=58 dogs) Group B (untreated; n=54 dogs)
Number of dogs with Esophagus Stomach Esophagus Stomach
No nodule 57 (98.3%) 58 (100%) 36 (66.7%) 53 (98.1%)
At least one nodule 1 (1.7%) 0 (0%) 18 (33.3%) 1 (1.8%)
Simple nodule(s) 1 (1.7%) 0 9 (16.7%) 1 (1.8%)
Operculated nodule(s) 0 0 13 (24.1%) 0
Ulcerated nodule(s) 0 0 2 (3.7%) 0
Tumor(s) 0 0 0 0
Table 3 Results of the endo-
scopic examination (n=112
dogs)
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